Paolo Di Giorgio
Chief Executive Officer at Angelini Ventures SpA
Profile
Elia is a visionary leader with a passion for innovation in healthcare, tech and life sciences and 20+ years of experience across industry, academic and clinical settings.
He is currently Managing Director of Angelini Ventures.
He is currently on the board of Genialis, an AI drug discovery company and a Venture Partner at First Star Ventures, a Boston based deep tech fund.
He served on the SAB of Alkahest, a regenerative medicine company later to sold to Grifols, and Healx, a UK fast-growing AI driven biotech company.
He has been/is an advisor also to fast growing startups ranging from biotech to healtech to deep tech such as Duality Technologies (Israel), Entropica Labs (Singapore), Cardea Bio (US), Pulse Infoframe (Canada), Etcembly (UK), Raremark (UK), as well as not for profits such as RebootRX (Boston) and Esperare Foundation (Switzerland).
Elia’s work has contributed to the understanding of the human genome and transcriptome, the diagnosis of rare disease patients, the development of gene therapy and novel drugs on the market and the development of ethics frameworks pertaining to the fast-changing world of big data in health and biology.
Elia holds a PhD in Computer Science from Leiden University and a Master of Research and Bachelor of Science in Biology from the University of York.
Paolo Di Giorgio active positions
| Companies | Position | Start |
|---|---|---|
Angelini Ventures SpA
 Angelini Ventures SpA Investment ManagersFinance Angelini Ventures SpA (Angelini Ventures) is a venture capital firm founded in 2022. The firm is headquartered in Rome, Italy. | Chief Executive Officer | 2022-04-30 |
Argobio SAS
 Argobio SAS Miscellaneous Commercial ServicesCommercial Services Argobio SAS is a start-up studio founded in 2021 and based in Paris, FR. The company was initiated by Kurma Partners, a leading healthcare venture capital firm based in France, and Bpifrance, the French national investment bank. The French company aims to nurture and launch at least five breakthrough biotech companies over the next five years by sourcing innovative early-stage projects from renowned European academic research institutions. The focus is on selected therapeutic areas, including rare diseases, neurological disorders, oncology, and immunology. Argobio will identify, select, and incubate these projects up to company creation and beyond, providing broad expertise in the discovery and development of novel drugs with a team of highly experienced biotech entrepreneurs. The internal team is led by Yves Ribeill, Neill Mackenzie, Poul Sørensen, and Rémi Soula. Thierry Laugel, Managing Partner at Partners, is the President of Argobio. Kurma and Bpifrance were joined by complementary strategic investors, Angelini Pharma, a private international pharmaceutical company, Evotec, a drug discovery alliance and development partnership company, and the Institut Pasteur, an internationally renowned center for biomedical research. | Director/Board Member | 2021-01-31 |
Q-State Biosciences, Inc.
 Q-State Biosciences, Inc. BiotechnologyHealth Technology Q-State Biosciences, Inc. operates as Biotechnology Company. It offers cardiology, neurology, toxicity screening, drug discovery, drug efficacy screening, pathology modeling, optogenetic, electrophysiology, voltage and calcium signal. The company was founded by Adam E. Cohen, Kevin Eggan, David Margulies and Joel Kralj and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 2014-08-31 |
Pretzel Therapeutics, Inc.
 Pretzel Therapeutics, Inc. BiotechnologyHealth Technology Pretzel Therapeutics, Inc. is an American biotechnology company that develops therapies by utilizing mitochondrial biology. Pretzel Therapeutics is based in an undisclosed location and has research facilities in another undisclosed location. The company aims to develop treatments that address the genetic causes of mitochondrial dysfunction. The company was founded by academic experts in mitochondrial biology and is supported by a world-class investor syndicate. Jay Parrish has been the CEO of the company since 2021. | Director/Board Member | - |
Former positions of Paolo Di Giorgio
| Companies | Position | End |
|---|---|---|
Novartis Venture Funds (USA)
 Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd | Corporate Officer/Principal | - |
Training of Paolo Di Giorgio
| Instituto de Empresa SL | Masters Business Admin |
| Harvard University | Undergraduate Degree |
| Alma Mater Studiorum - Università di Bologna | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Angelini Ventures SpA
Angelini Ventures SpA Investment ManagersFinance Angelini Ventures SpA (Angelini Ventures) is a venture capital firm founded in 2022. The firm is headquartered in Rome, Italy. | Finance |
Argobio SAS
Argobio SAS Miscellaneous Commercial ServicesCommercial Services Argobio SAS is a start-up studio founded in 2021 and based in Paris, FR. The company was initiated by Kurma Partners, a leading healthcare venture capital firm based in France, and Bpifrance, the French national investment bank. The French company aims to nurture and launch at least five breakthrough biotech companies over the next five years by sourcing innovative early-stage projects from renowned European academic research institutions. The focus is on selected therapeutic areas, including rare diseases, neurological disorders, oncology, and immunology. Argobio will identify, select, and incubate these projects up to company creation and beyond, providing broad expertise in the discovery and development of novel drugs with a team of highly experienced biotech entrepreneurs. The internal team is led by Yves Ribeill, Neill Mackenzie, Poul Sørensen, and Rémi Soula. Thierry Laugel, Managing Partner at Partners, is the President of Argobio. Kurma and Bpifrance were joined by complementary strategic investors, Angelini Pharma, a private international pharmaceutical company, Evotec, a drug discovery alliance and development partnership company, and the Institut Pasteur, an internationally renowned center for biomedical research. | Commercial Services |
Q-State Biosciences, Inc.
Q-State Biosciences, Inc. BiotechnologyHealth Technology Q-State Biosciences, Inc. operates as Biotechnology Company. It offers cardiology, neurology, toxicity screening, drug discovery, drug efficacy screening, pathology modeling, optogenetic, electrophysiology, voltage and calcium signal. The company was founded by Adam E. Cohen, Kevin Eggan, David Margulies and Joel Kralj and is headquartered in Cambridge, MA. | Health Technology |
Novartis Venture Funds (USA)
Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd | Finance |
Pretzel Therapeutics, Inc.
Pretzel Therapeutics, Inc. BiotechnologyHealth Technology Pretzel Therapeutics, Inc. is an American biotechnology company that develops therapies by utilizing mitochondrial biology. Pretzel Therapeutics is based in an undisclosed location and has research facilities in another undisclosed location. The company aims to develop treatments that address the genetic causes of mitochondrial dysfunction. The company was founded by academic experts in mitochondrial biology and is supported by a world-class investor syndicate. Jay Parrish has been the CEO of the company since 2021. | Health Technology |
- Stock Market
- Insiders
- Paolo Di Giorgio